Keywords: breast cancer; cardiovascular disease; endometrial cancer; estrogen-only; estrogen–progestagen; hip fracture; hormone replacement therapy; medroxyprogesterone acetate; menopausal hormone therapy; menopause; norethisterone; norgestrel; ovarian cancer; venous thromboembolism.